Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Moderna Eyes mRNA Plant in Japan, but Multi-Year Purchase Pact a Must: Local President
Moderna is eager to build a manufacturing plant in Japan for its mRNA-based products, but that should come with pull incentives such as the conclusion of purchase agreements with the government spanning multiple fiscal years, country chief Rami Suzuki tells…
To read the full story
Related Article
- Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
April 20, 2023
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
- Moderna CEO Visits Fukuoka for Potential Collaboration with Japan
September 13, 2022
- LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
- Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
March 14, 2022
- Moderna to Develop All Global Pipeline Assets in Japan without Delay: Local Chief
December 17, 2021
BUSINESS
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
- Chugai Files Enspryng for MOGAD Relapse Prevention in Japan
August 3, 2026
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…